University College of London Hospitals - Articles and news items

UK Phase 2/3 acid sphingomyelinase deficiency trial begins

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Olipudase alfa is an enzyme replacement therapy being studied as a treatment of non-neurological manifestations of acid sphingomyelinase deficiency (ASMD)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+